LOVELAND, Colo., Oct. 6, 2011 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA), a provider of advanced veterinary diagnostic and other specialty veterinary products, today announced The Patent Board, a leading independent provider of best practices research, tools and metrics for patent analysis and intellectual property investment (http://www.patentboard.com), has ranked Heska's Science Strength in the top 50 of the Biotechnology industry. More information can be obtained at the following weblink: http://online.wsj.com/mdc/public/page/2_3022-macromkt.html.
"We are pleased a respected third party has chosen to recognize our Science Strength," said Dr. Robert Grieve, Heska's Chairman and CEO. "The quality of our scientific efforts and the potential value of our substantial intellectual property value are assets we feel are often overlooked."
As of September 30, 2011, Heska owns, co-owns or has rights to 196 issued U.S. patents and six pending U.S. patent applications with a corresponding foreign patent portfolio including 131 issued foreign patents and 21 patent applications in various foreign countries. Heska's issued and pending patent portfolios primarily relate to heartworm control, flea control, allergy, infectious disease vaccines, diagnostic and detection tests, immunomodulators, instrumentation, nutrition, pain control and vaccine delivery technologies.
Heska Corporation (NASDAQ: HSKA) sells advanced veterinary diagnostic and other specialty veterinary products. Heska's state-of-the-art offerings to its customers include diagnostic instruments and supplies as well as single use, point-of-care tests, pharmaceuticals and vaccines. The company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled customer support to veterinarians. For further information on Heska and its products, visit the company's website at www.heska.com.
|SOURCE Heska Corporation|
Copyright©2010 PR Newswire.
All rights reserved